BioPharmSignal logoBioPharmSignal

Biotech News

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena (TRVN)TrevenaCompany update

TRVN (TRVN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is trvn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Trevena

Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.

Recent company news

TRVNTrevena2024-11-07 12:01 EST

Trevena Reports Third Quarter 2024 Results and Provides Business Update

TRVNTrevena2024-10-04 20:05 EST

Trevena Announces Receipt of Nasdaq Delisting Notification

TRVNTrevena2024-08-08 20:05 EST

Trevena Announces Reverse Stock Split

TRVNTrevena2024-08-08 11:00 EST

Trevena Reports Second Quarter 2024 Results and Provides Business Update

TRVNTrevena2024-07-08 13:15 EST

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States